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Background
In sub-Saharan Africa, where the effects of human immu-
nodeficiency virus type 1 (HIV-1) have been most devas-
tating, there are multiple subtypes of this virus. The
distribution of different subtypes within African popula-
tions is generally not linked to particular risk behaviours.
Thus, Africa is an ideal setting in which to examine the
diversity and mixing of viruses from different subtypes on
a population basis. Objectives: To determine the subtypes
of human immunodeficiency virus -1 (HIV-1) circulating
in a HIV-positive drug naive populations Nairobi, Kenya.
Methods
In this study, 78 blood samples were sampled randomly
and peripheral mononuclear cells (PBMCs) separated.
Total proviral DNA was used in nested polymerase chain
reaction to amplify 697 bp HIV Pol region. The PCR
amplimers were cloned and partially sequenced. Gener-
ated sequences were aligned and phylogenetically ana-
lysed using known reference subtypes sequences.
Results
The distribution of subtypes in this population was as fol-
lows: subtype A, 39(50%); subtype D, 8(10.25%); sub-
type C, 28(35.9%); and CRF A1D, 3(3.0%). Based on the
small sample size analysed, the 3.0% intersubtype recom-
binants detected suggested, there is a higher levels in
Kenya and in other parts of Africa where are multiple sub-
types.
Conclusion
Our analysis indicated that HIV subtypes in Nairobi prov-
ince of Kenya are predominated by subtypes A1. Addition-
ally, the detection of high prevalence of recombinant
forms indicates viral mixing in among the population,
possibly as a result of dual infections.
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